Get the Stockscreener App
1.365
2.14%
-0.035
Pds Biotechnology Corporation stock is traded at $1.365, with a volume of 133.74K.
It is down -2.14% in the last 24 hours and down -2.14% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$1.40
Open:
$1.39
24h Volume:
133.74K
Relative Volume:
0.20
Market Cap:
$62.39M
Revenue:
-
Net Income/Loss:
$-40.56M
P/E Ratio:
-1.1667
EPS:
-1.17
Net Cash Flow:
$-35.28M
1W Performance:
-13.29%
1M Performance:
-2.14%
6M Performance:
-37.44%
1Y Performance:
-53.56%
1-Day Range:
$1.33
$1.4251
1-Week Range:
$1.33
$1.575
52-Week Range:
$0.8505
$4.42
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Name
Pds Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.365 | 71.76M | 0 | -40.56M | -35.28M | -1.17 |
|
ONC
Beone Medicines Ltd Adr
|
246.59 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.68 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.89 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.00 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corporation Stock (PDSB) Latest News
PDS Biotechnology files to sell 9.82M shares of common stock for holders - MSN
PDS Biotechnology (PDSB) Announces Plan to Offer 9.82 Million Sh - GuruFocus
PDS Biotechnology (PDSB) Plans Sale of 9.82 Million Shares | PDS - GuruFocus
Wall Street Zen Upgrades PDS Biotechnology (NASDAQ:PDSB) to “Hold” - Defense World
PDS Biotechnology Corporation (PDSB)’s Versamune HPV Surpasses Survival Benchmarks in Recurrent Head and Neck Cancer Trial - Insider Monkey
Transcript : PDS Biotechnology CorporationSpecial Call - marketscreener.com
Q2 EPS Estimates for PDS Biotechnology Raised by B. Riley - Defense World
PDS Biotech reports extended survival in HPV cancer study - Investing.com Australia
PDS Biotech reports extended survival in HPV cancer study By Investing.com - Investing.com India
PDS Biotechnology Reports Promising Overall Survival Data for Versamune® HPV Combined with Pembrolizumab in HPV16-Positive Head and Neck Cancer - Nasdaq
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - TradingView
PDS Biotech at A.G.P. Showcase: Versamune’s Promising Potential By Investing.com - Investing.com South Africa
PDS Biotech at A.G.P. Showcase: Versamune’s Promising Potential - Investing.com
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase - The Manila Times
PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2025 Earnings Call Transcript - MSN
PDS Biotech outlines continued VERSATILE 003 Phase 3 expansion while advancing HPV16-positive head and neck cancer strategy - MSN
Raymond James Financial Inc. Takes $26,000 Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology Corp (PDSB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
PDS Biotechnology Reports Q1 2025 Progress and Financials - TipRanks
PDS Biotech advances Phase 3 trial, reports Q1 financials By Investing.com - Investing.com Nigeria
PDS Biotechnology: Q1 Earnings Snapshot - Midland Daily News
EMV Capital portfolio company PDS Biotech advances cancer trial - Proactive Investors
PDS Biotech advances Phase 3 trial, reports Q1 financials - Investing.com Australia
Earnings call transcript: PDS Biotech’s Q1 2025 results show reduced losses - Investing.com
Transcript : PDS Biotechnology Corporation, Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
PDSB Advances with Phase 3 Trial for Versamune HPV Therapy | PDS - GuruFocus
PDS Biotechnology Corporation Initiates VERSATILE-003 Phase 3 Trial and Announces Abstracts Selected for ASCO 2025 - Nasdaq
PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update - TradingView
PDS Biotechnology (PDSB) Expected to Announce Earnings on Wednesday - Defense World
Pds Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
PDS Biotechnology Unveils Promising Flu Vaccine Data - TipRanks
PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting - The Manila Times
PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results - TradingView
Marshall Wace LLP Has $64,000 Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Renaissance Technologies LLC Acquires 76,800 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
THE CANADIAN INTERNATIONAL TRADE TRIBUNAL TERMINATES ITS PRELIMINARY INJURY INQUIRY IN RESPECT OF TIDEWATER RENEWABLES LTD.'S COUNTERVAILING (ANTI-SUBSIDY) AND ANTI-DUMPING DUTY COMPLAINT RELATING TO I - The Globe and Mail
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Call Transcript - MSN
PDS Biotechnology Enters $20M Securities Purchase Agreement - TipRanks
B. Riley Adjusts Price Target on PDS Biotechnology to $5 From $7, Maintains Buy Rating - marketscreener.com
B. Riley Expects Stronger Earnings for PDS Biotechnology - Defense World
PDS Biotechnology Director Sir Richard Sykes Retires - TipRanks
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
PDS Biotechnology Corporation Announces Three Abstracts Accepted for ASCO 2025 on Versamune® HPV Immunotherapy - Nasdaq
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting - The Manila Times
Raymond James Financial Inc. Takes Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Pds Biotech Announces Pds01adc Clinical Data To Be Presented At The American Association For Cancer Research - MarketScreener
Pds Biotechnology Corporation Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pds Biotechnology Corporation Stock (PDSB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Glover Stephen C. | Director |
Feb 28 '25 |
Buy |
1.66 |
15,061 |
25,001 |
78,851 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):